WHO recommends two monoclonal antibody medications to treat Ebola

The World Health Organization (WHO) on Friday recommended two monoclonal antibody treatments against Ebola, saying the use of such drugs combined with better care had “revolutionized” the treatment of a disease once seen as a near-certain killer.

The drugs – Regeneron’s Inmazeb (REGN-EB3) and Ridgeback Bio’s Ebanga (mAb114) – use laboratory-made monoclonal antibodies that mimic natural antibodies in fighting off infections.

DEADLY EBOLA-LIKE MARBURG VIRUS COULD ‘SPREAD FAR AND WIDE’ IF NOT STOPPED: WHO

“Advances in supportive care and therapeutics over the past decade have revolutionized the treatment of Ebola. Ebola virus disease used to be perceived as a near certain killer. However, that is no longer the case,” said Robert Fowler, a professor at the University of Toronto, Canada, and co-chair of WHO’s guideline development group. Effective care and the use of these treatments now leads to the recovery of the “vast majority” of people from Ebola, he said, without giving specific data.

EBOLA MAY HAVE LINGERED IN A SURVIVOR FOR 5 YEARS BEFORE SPARKING NEW OUTBREAK

The new recommendations follow trials of the drugs against the hemorrhagic fever in Democratic Republic of Congo during a 2018-2020 outbreak there. Dr Janet Diaz, lead of the clinical management unit in WHO’s Health Emergencies program, told journalists the drugs were currently available in Congo but more work was needed to improve affordability.

Find more, like the above, right here on Cryptopolytech.com by following our extensive quiclick links appearing on images or within categories [NEWSer CHEWSer].

Source Information (if available)

It appears the above article may have originally appeared on www.foxnews.com and has been shared elsewhere on the internet, repeatedly. News articles have become eerily similar to manufacturer descriptions.

We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.